By Ron Shinkman, Editor, Laboratory Industry Report
Startup Theranos has experienced another blow as the Centers for Medicare & Medicaid Services (CMS) has issued a letter to the firm saying its Newark, CA laboratory presents a potential danger to patients and it does not meet…
Read more...
By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies
A substantial proportion of relapsed or refractory pediatric solid tumors have actionable alterations, according to a study published Jan. 28 in JAMA Oncology. The authors say that clinical tumor profiling to individualize cancer therapy (iCat) recommendations is
…
Read more...
By Kelly A. Briganti, Editorial Director, G2 Intelligence
Last year the FDA held workshops to discuss analytical standards for next-generation sequencing (NGS) and use of curated databases for establishing clinical relevance of genetic variants. The FDA continues its engagement with stakeholders regarding NGS technology, this year fostering public discussion regarding…
Read more...
By Stephanie Murg, Managing Director, G2 Intelligence
A multi-platform genomic analysis—the largest undertaken to date—of gliomas has shed new light on these, the most common malignant brain tumors. The results of the multinational molecular profiling study, published in the January 28 issue of Cell, make a case for…
Read more...
By Kelly A. Briganti, Editorial Director, G2 Intelligence
A new year is a time for reflection and resolutions. For compliance officers that means evaluating compliance risks and current compliance programs and looking for ways to improve. G2 Compliance Advisor surveyed health care attorneys who…
Read more...
WEBINAR ANNOUNCEMENT
Speakers:
Cheryl Hess, MS, CGC, Genetic Counselor, NextGxDx
Jessie Conta, MS, LCGC, Genetic Counselor, Department of Laboratories, Seattle Children's Hospital
Utilization management is a timeless issue for the health care industry and the laboratory sector in particular. The issue is even more complicated in the area of genetic testing, due to the explosion of the number of tests available and the increasing number of laboratories offering such tests, differences in cost for comparable assays and the need for clarity concerning tests' necessity and contribution to patient care. This conference will illustrate that utilization management need not be an oppositional positioning of competing interest groups, but rather can be an opportunity to bring together all parties in the health care delivery system to improve healthcare value for physicians, patients, hospitals, laboratories and payers.
Attend this G2 Webinar to learn about:
- the rapid evolution of the genetic testing marketplace
- three common challenges when considering UM interventions
- practical tactics regarding how and where to intervene in the test ordering process
- the importance of UM allies within commercial laboratories
- the value of data metrics and analytics in driving UM success
When: February 24, 2016, 2-3:30pm Eastern
Click here to register, or call Customer Service at 1-888-729-2315
|
